2021 EBMT Annual Meeting | Supplements And Featured Publications

Narsoplimab Elicits Responses Across High-Risk HSCT-TMA Subtypes

March 16, 2021

The MASP-2 inhibitor narsoplimab demonstrated high response rates and a significant improvement in laboratory markers and organ function irrespective of subgroup in adult patients with high-risk hematopoietic stem cell transplant–associated thrombotic microangiopathy.

AB-205 Shows Tolerability, Robust Effects in Patients With Lymphoma Undergoing HDT-ASCT

March 16, 2021

The engineered cord endothelial cell product AB-205 showed an encouraging safety profile along with robust effects in eliminating oral/gastrointestinal severe regimen-related toxicities in patients with systemic lymphoma undergoing high-dose therapy and autologous hematopoietic stem cell transplantation.

x